Posts Tagged ‘tirzepatide’

Want to Control Hypertension? Treating Obesity Helps

February 8, 2024 — This is not exactly startling news. But two new studies this week do offer a very clear confirmation of one of the important benefits that comes from treating obesity – unmistakably better control of hypertension. One reason this is important is the substantial amount of disinformation that circulates to suggest obesity is not a real […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Who Gets and Fills Prescriptions for Obesity Medicines?

January 31, 2024 — Obesity is the most prevalent chronic disease in America, so you might think that prescriptions for obesity medicines are relatively common – but only if you are unfamiliar with prevailing attitudes about these medicines. Because in fact, even in a large health system known for excellent care in cardiometabolic health, these prescriptions are rather rare. […]

Weight Regain in the Real World vs a Placebo-Controlled Trial

January 30, 2024 — It created quite a stir last week when Epic Research published an analysis suggesting that weight regain in the real world does not look the same as a placebo-controlled trial. After all, regain is quite an important subject. Obesity is clearly a chronic disease, requiring chronic care. But lots of people try to avoid this […]

Disrespecting People Who Want to Feel and Look Their Best

January 21, 2024 — Seriously, it is not a problem if people living with obesity value their appearance. Do we really have to say this? Apparently we do. Because all too often we see a subtle bias in discourse about obesity that adds up to disrespecting people who want to look and feel their best. Physician and writer Matthew […]

From Boom to Bust in Compounded GLP-1 Medicines

January 16, 2024 — If you wonder why the Obesity Action Coalition, Obesity Medicine Association, and the Obesity Society all warn against using compounded versions of GLP-1 medicines for obesity, consider the boom and bust story of ACA Pharmacy in Nashville, Tennessee. After semaglutide went into shortage in 2022, it began doing a booming business with a compounded version […]

LillyDirect Poised to Shake Up Access to Obesity Care

January 5, 2024 — Eli Lilly and Company has taken the unusual step of starting a direct to consumer clinical care and pharmacy program for obesity, diabetes, and migraine. If you have any doubt that LillyDirect will shake up the landscape for access to obesity care, just ask the folks at WeightWatchers. Their stock dropped by 11% yesterday when […]

What Comes from 88 Weeks of Tirzepatide? Or Stopping It?

December 13, 2023 — NB: An earlier version of this post reflected confusion of time periods in this study. We regret the error. “The long run is a misleading guide to current affairs. In the long run we are all dead,“ wrote John Maynard Keynes. But Keynes was obviously not a doctor. So his words don’t hold much sway […]

As Zepbound Launches, Will Access to Obesity Meds Improve?

December 6, 2023 — The Zepbound brand of tirzepatide is now available in U.S. pharmacies. This is a big deal because this launch marks the emergence of serious competition for advanced obesity medicines. Even (or perhaps especially) in healthcare, money indeed makes the world go around and one of the best checks on greed is competition. So as Zepbound […]

The Catch-Up Game Begins in Obesity and Diabetes Medicines

November 25, 2023 — Two weeks ago, a shift started in the public messaging about semaglutide supply issues that have dogged Novo Nordisk from the very beginning of launching a version of this drug (Wegovy) for obesity. Has the catch-up game in production capacity for obesity and diabetes medicines begun at last in earnest? At the beginning of November, […]